Metropolis Healthcare has reported a strong start to FY27, with consolidated revenue climbing 17% year-on-year to Rs. 450 crore in the first quarter ended June 30, 2026.

 

India’s second-largest pathology laboratory chain posted a 27% YoY rise in EBITDA to Rs. 113 crore, while profit after tax (PAT) increased 26% to Rs. 57 crore, reflecting robust operational execution and improving business momentum.

 

The company’s growth was powered by a steady increase in demand for trusted diagnostic services, with patient volumes rising 10% YoY and test volumes growing 11% YoY. Metropolis said the performance reflects deeper market penetration and the continued shift towards organised, science-led diagnostic providers.

 

B2C revenue grew 18% YoY, supported by strong brand recall, targeted micro-marketing initiatives and rising digital engagement. B2B revenue increased 15% YoY, driven by improving business quality and an expanding network of clinicians and institutional partners.

 

The company’s portfolio segments continued to gain traction, with TruHealth revenue growing 22% YoY to Rs. 81 crore, contributing 18% to the segment mix. Specialty diagnostics revenue rose 17% YoY to Rs. 178 crore, accounting for 40% of the segment mix. Premium TruHealth packages recorded over 50% growth, while radiology-integrated wellness packages increased more than 40%.

 

Revenue per Patient (RPP) improved 6% YoY, while Revenue per Test (RPT) rose 5% YoY, driven by a richer diagnostic mix and increased contribution from specialised testing.

 

Tier III cities emerged as the fastest-growing markets for Metropolis, with revenue rising around 25% YoY. This compared with 11% growth in Tier I cities and 14% in Tier II markets, highlighting the company’s expanding footprint beyond major urban centres.

 

Commenting on the performance, Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited, said, "The diagnostics industry is consolidating around trusted, science-led providers as patients increasingly prioritise quality, accuracy and specialised care. Our investments in scientific innovation, strategic acquisitions and network expansion continue to strengthen Metropolis' leadership across key markets, particularly in North India, while broadening our differentiated diagnostics offering. 

 

"This quarter, we delivered 17% revenue growth through higher volumes without any price increase, reflecting the continued confidence that patients and clinicians place in the Metropolis brand. As we continue to scale, our focus remains on making high-quality diagnostics more accessible while creating sustainable long-term value for all our stakeholders."

 

Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited, said, “Our strong start to the year reflects disciplined execution and the resilience of our business model. Healthy growth in patient and test volumes, together with a 210-basis point expansion in EBITDA margin, demonstrates the quality of our growth and the scalability of our operating model. Continued momentum in Specialty diagnostics and TruHealth reflects the strength of our portfolio. We remain focused on enhancing productivity, driving operational excellence and delivering sustainable, profitable growth.”

 

Metropolis said its focus remains on expanding access to high-quality diagnostics, strengthening its specialised offerings and driving sustainable growth through operational excellence and innovation.